Life Sciences Global Capability

Size: px

Start display at page:

Download "Life Sciences Global Capability"

Gloria Davidson
5 years ago
Views:

1 Life Sciences Global Capability

Integrating ingenuity Through a dedicated team of professionals specialising in investment sales, construction, leasing, facility management, finance and industry specialist development, we provide

With a major presence in each of the key life science markets in the United States, Canada, Europe and Asia, we provide our clients with global coverage backed by a local perspective.

We have taken an innovative approach to advising our clients in this sector by providing the expertise of a life sciences professional, making us the only commercial real estate company to have

Key UK and global knowledge areas: Product life cycle Patent expiration/patent Box/IPs Multiple indications FDA & MHRA approvals Payer landscape Obamacare, Private insurance, NHS GMC regulations

Importance of phase II and phase III trials Capability clusters Mergers and acquisitions Co-promotion Venture capitalist R&D tax credits HRA/NIHR Pharmaceutical and biotech in-house specialist

the sector s increasing pipeline of new drug development.

2 Integrating ingenuity Through a dedicated team of professionals specialising in investment sales, construction, leasing, facility management, finance and industry specialist development, we provide innovative real estate solutions to the life science industry worldwide. With a major presence in each of the key life science markets in the United States, Canada, Europe and Asia, we provide our clients with global coverage backed by a local perspective. We have earned a solid reputation for rapid, on-time and under budget delivery of the most sophisticated projects for the world s leading life science companies. We have taken an innovative approach to advising our clients in this sector by providing the expertise of a life sciences professional, making us the only commercial real estate company to have in-house access to this specialist knowledge. Key UK and global knowledge areas: Product life cycle Patent expiration/patent Box/IPs Multiple indications FDA & MHRA approvals Payer landscape Obamacare, Private insurance, NHS GMC regulations Impact on name brand Increase in generics utilisation New compounds entering the market Product launch New disease states, indications and market impact NICE regulations Generic utilisation Importance of phase II and phase III trials Capability clusters Mergers and acquisitions Co-promotion Venture capitalist R&D tax credits HRA/NIHR Pharmaceutical and biotech in-house specialist Colliers International is one of the first property agencies to offer our clients the expertise of a life sciences specialist, Kaleigh Haeg, who understands the specific requirements to accommodate the sector s increasing pipeline of new drug development. With more than seven years of experience, Kaleigh Haeg represents both landlords and tenants providing them with a unique insight into the pharmaceutical and biotech markets. Kaleigh was previously based in Los Angeles with Avanir Pharmaceuticals where she worked for two years as their number one sales representative. Prior to this, she spent more than five years with Eisai Pharmaceuticals and again was their number one sales representative. She has also worked in co-promotion with Pfizer, Merck and Johnson&Johnson, specialising in neuroscience, obesity, diabetes and oncology. Her extensive market knowledge comes from an in-depth understanding of the complexity of selling in various therapeutic areas and her experience in working with a variety of different sized companies. She is also able to provide insight into the US and other global markets and the need for diversification in product portfolios. To find out more, please contact: Kaleigh Haeg Life Sciences Specialist kaleigh.haeg@colliers.com P. 2 LIFE SCIENCES Colliers International Colliers International LIFE SCIENCES P. 3

Benefits of teaming up with us: > Understanding of unique client product needs and in-depth industry knowledge > Global coverage in major biopharmaceutical clusters and emerging markets Elements of

3 Benefits of teaming up with us: > Understanding of unique client product needs and in-depth industry knowledge > Global coverage in major biopharmaceutical clusters and emerging markets Elements of success Colliers focuses on accelerating success for its clients by seamlessly providing a full range of services to real estate users, owners and investors worldwide, including global corporate solutions, brokerage, property and asset management, project management, valuation and advisory, investment sales and consulting services. > In-house specialist for pharmaceutical and biotechnology clients > Protection of intellectual property > Our specialist provides an analytical review of pipeline, product portfolio, market trends and future goals > Demonstrated track record > Project management > Rapid, on-time and under-budget delivery > Strong relationships with industry disciplines including engineering, design and development > Economic grant or incentive negotiation > Bench strength of an integrated team > Innovative approach to understanding our clients P. 4 LIFE SCIENCES Colliers International Colliers International LIFE SCIENCES P. 5

Bt CLIENT STRATEGY Re Research & Development Pc Pre-Clinical C Clinical Co Commercialisation D Development Fl FDA Approval/Launch Pi Pilot Scale Manufacturing Nda New Drug Application Pe Patent

4 Bt CLIENT STRATEGY Re Research & Development Pc Pre-Clinical C Clinical Co Commercialisation D Development Fl FDA Approval/Launch Pi Pilot Scale Manufacturing Nda New Drug Application Pe Patent Expiration Bt Bio-Technology Bi Bio-Informatics Mt Medical Technology Life Sciences Pe Re Mt Bi Pi Fl Nda Product development timeline Basic research Preclinical R&D Clinical Phase I Clinical Phase II Clinical Phase III Preregistration LAUNCH Life Sciences Pharmaceuticals Biopharmaceuticals Pc L C D Co Entry in to humans Marketing authorisation application STAGE OBJECTIVES PROBABILITY OF REACHING LAUNCH PHARMACEUTICAL DURATION (YEARS) BIOLOGICS DURATION (YEARS) BIO SIMILAR DURATION (YEARS) 1 Understand disease mechanisms Identify targets and compounds against them 0.1% 3 to 5 1 to 4 2 to 3 COLLIERS SERVICES P Portfolio Optimisation Pm Project Management & Delivery P Ie 2 3 Test candidate drugs in laboratory, in-vivo/in-vitro, side-effects and therapeutic value Test safety on healthy volunteers ( people) 1% 1 to 2 2 to 4 4 to 5 5% 1 to 2 5 to 7 5 to 7 Ma M&A Support & Consulting Wo Workplace Consulting Is Incentives & Site Selection Cs Corporate Real Estate Strategy F Facilities Planning Ie Industry Specialist Va Valuation & Appraisal Client Strategy Colliers Services Wo F Ma Is Test efficacy in targeted disease (in people). Determine appropriate dose Confirm efficacy in larger patient populations (300-3,000 people) FDA/EMEA reviews 100,000 page application and decides whether to grant approval 10% 1 to 2 7 to 9 7 to 8 50% 2 to 3 10 to % 1 to 2 12 to P. 6 LIFE SCIENCES Colliers International Pm Va Cs Colliers International LIFE SCIENCES P. 7

5 The UK market Key UK market statistics: UK pharmaceutical exports of 21.3 billion ranked no.8 in the world in of the world s top 75 medicines were discovered and developed in Britain Everyday 12.1 million is invested in the UK through research and development from the pharmaceutical industry The UK has won 46 Nobel prizes in the last 50 years. Key Nobel prize winners include:»» John O Keefe - Physiology/Medicine 2014»» Peter Higgs - Physics 2013»» John Gurdan - Physiology/Medicine 2012 The UK pharmaceutical market comprises 116 companies and employs 73,000 professionals The UK biotechnology market comprises 455 companies and employs 22,400 Glossary of terms Pharmaceutical sector Companies who engage in research, developing, manufacturing, and marketing drugs. Defining illness is not necessarily their mission. Generally, the medications produced target diseases that have been defined previously by the medical professionals. Generic utilisation is less restricted and easy to replicate. Biotechnology sector Biotechnology is the use of living systems and organisms to develop or make products, or any technological application that uses biological systems, living organisms or derivatives thereof, to make or modify products or processes for specific use. Biologics sector Companies whose primary commercial activity depends on the use of microorganisms or highly complex proteins from genetically-modified living cells as components in medications to treat various diseases and conditions, from cancer to rheumatoid arthritis to multiple sclerosis. These medications are called Biologics. Restrictions for generic replication or Biosimilars makes it harder to recreate. Medical technology sector Includes a wide range of healthcare products and is used to diagnose, monitor or treat diseases or medical conditions affecting humans. P. 8 LIFE SCIENCES Colliers International Colliers International LIFE SCIENCES P. 9

Glossary of terms (cont.) Our global business FDA: (Food and Drug Administration) US regulatory agency responsible for the safety and efficacy of medical drugs and devices.

Colliers International is a leader in global real estate services defined by our spirit of enterprise.

GMC: (General Medical Council) Set standards for doctors and students in the UK.

6 Glossary of terms (cont.) Our global business FDA: (Food and Drug Administration) US regulatory agency responsible for the safety and efficacy of medical drugs and devices. FDA reviews new drug applications, implements standards, and regulates the sale of restricted drugs. Colliers International is a leader in global real estate services defined by our spirit of enterprise. Through a culture of service excellence, and a shared sense of initiative, we have integrated the resources of real estate specialists worldwide to accelerate the success of our clients. GMC: (General Medical Council) Set standards for doctors and students in the UK. GMP: (Good manufacturing practice) Quality assurance aimed primarily at diminishing the risks inherent in any pharmaceutical production. HRA: (Health Research Authority) Protects and promotes the interests of patients and the public in health research, and in streamlining the regulation of research. IP: (Intellectual Property) Protection of product. MHRA: (Medicines and Healthcare products Regulatory Agency) UK regulatory agency responsible for the safety and efficacy of medical drugs and devices. MHRA works in accordance with the European Community s directive and UK law. NICE: (National Institute for Health and Care Excellence) Provides national guidance and advice to improve health and social care. NIHR: (National institute of Health Research) UK government body that coordinates and funds research for the National Health Service. NHS: (National Health Service NHS) The publicly funded national healthcare system in the United Kingdom. The organisation, funded primarily by taxation, provides free or low-cost healthcare to all legal residents of the UK. OBAMACARE: (Affordable Care Act) A US law aimed at reforming the American healthcare system. The foundation of our service is the strength and depth of our specialists. Our clients can depend on our ability to draw on years of direct experience in the local market. Our professionals know their specialist markets inside out. Whether you are a local firm or a global organisation, we provide creative solutions for all your real estate needs. Colliers International offers a comprehensive portfolio of real estate services to occupiers, developers, owners and investors on a local, regional, national and international basis. Services Sectors Agency Sales & Leasing Hotels Landlord Representation Industrial & Logistics Tenant Representation Life Sciences Capital Markets & Investment Services Mixed Use Corporate Solutions Residential Investment Property Management Valuation & Advisory Services $2.3B IN ANNUAL REVENUE (US DOLLARS) P. 10 LIFE SCIENCES Colliers International SPECIALIST SERVICES SPECIALIST SECTORS > Building Surveying > Automotive & Roadside > Business Rates > Banking > Corporate Restructuring & Recovery > Healthcare > Destination Consulting > Metals & Mining > Development Consulting > Public Sector > Fund Management > Resorts > Lease Advisory > Sports & Culture > Planning > Waste, Energy & Minerals > Licensed & Leisure > Property & Project Finance > Research & Forecasting > Sustainability Solutions Office Project Management In addition to our core sectors and services, in the UK we offer specialist expertise in niche sectors. Retail 1.7B SQUARE FEET UNDER MANAGEMENT 502 OFFICES 16,300 PROFESSIONALS 67 COUNTRIES Colliers International LIFE SCIENCES P. 11

7 Colliers International 50 George Street London W1U 7GA colliers.com/uklifesciences All information, analysis and recommendations made for clients by Colliers International are made in good faith and represent Colliers International s professional judgement on the basis of information obtained from the client and elsewhere during the course of the assignment. However, since the achievement of recommendations, forecasts and valuations depends on factors outside Colliers International s control, no statement made by Colliers International may be deemed in any circumstances to be a representation, undertaking or warranty, and Colliers International cannot accept any liability should such statements prove to be inaccurate or based on incorrect premises. In particular, and without limiting the generality of the foregoing, any projections, financial and otherwise, in this report are intended only to illustrate particular points of argument and do not constitute forecasts of actual performance. Colliers International is the licensed trading name of Colliers International Business Space UK LLP which is a limited liability partnership registered in England and Wales with registered number OC Our registered office is at 50 George Street, London W1U 7GA

Financial modelling. Corporate Finance PRECISE. PROVEN. PERFORMANCE.

Financial modelling. Corporate Finance PRECISE. PROVEN. PERFORMANCE. Financial modelling Corporate Finance PRECISE. PROVEN. PERFORMANCE. Financial modelling Businesses seeking capital are faced with an obligation to provide financial projections to potential stakeholders.